Drug intelligence / Profile preview

cyclobenzaprine + naproxen

Development stage
Phase 4
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

Cyclobenzaprine + naproxen is a combination therapy consisting of two distinct pharmaceutical agents: cyclobenzaprine, a centrally acting skeletal muscle relaxant, and naproxen, a nonsteroidal anti-inflammatory drug (NSAID). Cyclobenzaprine works primarily by reducing tonic somatic motor activity influencing both alpha and gamma motor neurons, thereby alleviating muscle spasm associated with acute musculoskeletal conditions. Naproxen inhibits the enzyme cyclooxygenase (COX), decreasing the formation of prostaglandins involved in pain, inflammation, and fever. This combination is used short-term in the management of acute conditions characterized by muscle spasm, pain, and inflammation, such as acute low back pain or musculoskeletal injuries. There are no known major pharmacokinetic interactions between the two drugs, and their combined use can provide more comprehensive relief than either alone in certain cases. However, side effects—primarily drowsiness (from cyclobenzaprine) and gastrointestinal discomfort or increased risk of GI bleeding (from naproxen)—are more common when combined. The combination should be limited to short, temporary courses (frequently not exceeding 2–3 weeks)[1][2][3][8].

02

Targets

5-HT2 (5-HT2 receptor family)HTR6 (5-hydroxytryptamine receptor 6)HTR7 (5-hydroxytryptamine receptor 7)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)ADRA1A (α1A)ADRA2A (α2A)

Beyond the preview

Go deeper on cyclobenzaprine + naproxen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclobenzaprine + naproxen.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call